125 related articles for article (PubMed ID: 38805424)
1. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
5. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
6. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
7. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
Vaidyanathan G; Strickland DK; Zalutsky MR
Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
[TBL] [Abstract][Full Text] [Related]
8. The utility of
Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
12. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Tanabe A; Naruse M; Nomura K; Tsuiki M; Tsumagari A; Ichihara A
Horm Cancer; 2013 Apr; 4(2):103-10. PubMed ID: 23361939
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of radionuclide treatment using α-emitting meta-
Ohshima Y; Sudo H; Watanabe S; Nagatsu K; Tsuji AB; Sakashita T; Ito YM; Yoshinaga K; Higashi T; Ishioka NS
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):999-1010. PubMed ID: 29350258
[TBL] [Abstract][Full Text] [Related]
15. Tumour size: the only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma.
Nguyen HH; Proye CA; Carnaille B; Combemale F; Pattou FN; Huglo D
Aust N Z J Surg; 1999 May; 69(5):350-3. PubMed ID: 10353549
[TBL] [Abstract][Full Text] [Related]
16. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K
Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effects and potential therapeutic response biomarkers in α-emitting
Ohshima Y; Kono N; Yokota Y; Watanabe S; Sasaki I; Ishioka NS; Sakashita T; Arakawa K
Theranostics; 2019; 9(6):1538-1549. PubMed ID: 31037122
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
[TBL] [Abstract][Full Text] [Related]
20. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]